Go Pro
→ They didn't warn anyone in 1971. This time someone is warning you. (From Reagan Gold Group) (Ad)tc pixel
OTCMKTS:NWBO

Northwest Biotherapeutics Q2 2026 Earnings Report

Northwest Biotherapeutics logo
$0.19 +0.00 (+1.05%)
As of 08/14/2026 03:59 PM Eastern
ProfileEarnings History

Northwest Biotherapeutics EPS Results

Actual EPS
-$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Northwest Biotherapeutics Revenue Results

Actual Revenue
$0.81 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Northwest Biotherapeutics Announcement Details

Quarter
Q2 2026
Date
8/14/2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Northwest Biotherapeutics Earnings Headlines

Northwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance Company
August 6, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-mou-for-collaboration-with-the-saudi-pharmaceutical-industries-and-medical-appliance-company-302845199.html
NORTHWEST BIOTHRPUTCS INC by Northwest Biotherapeutics, Inc. Insider Trading Activity
July 18, 2026  |  benzinga.comhttps://www.benzinga.com/quote/NWBO/insider-trades
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.tc pixel
August 16 at 1:00 AM  |  Investors Alley (Ad)
Northwest Biotherapeutics, Inc.: Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax-L For Glioblastoma Using Individual Patient Level Data ...
July 8, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-07/68978081-northwest-biotherapeutics-inc-northwest-biotherapeutics-presents-updated-survival-data-from-phase-iii-trial-of-dcvax-l-for-glioblastoma-using-indiv-008.htm
Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses
July 8, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/northwest-biotherapeutics-presents-updated-survival-data-from-phase-iii-trial-of-dcvax-l-for-glioblastoma-using-individual-patient-level-data-in-multiple-independent-analyses-302821113.html
Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting
July 2, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-scientific-presentation-on-propensity-score-matching-at-the-british-neuro-oncology-society-annual-meeting-302817146.html
See More Northwest Biotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Northwest Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Northwest Biotherapeutics and other key companies, straight to your email.

About Northwest Biotherapeutics

Northwest Biotherapeutics (OTCMKTS:NWBO) is a clinical-stage biotechnology company focused on the development of personalized dendritic cell immunotherapies for the treatment of cancer. The company’s proprietary platform harnesses patient-derived dendritic cells to present tumor-specific antigens and stimulate a targeted immune response. By tailoring each vaccine to the individual patient’s tumor profile, the approach aims to improve outcomes and reduce off-target toxicity associated with conventional therapies.

The company’s lead candidate, DCVax®-L, is designed for patients with newly diagnosed or recurrent glioblastoma multiforme (GBM) and has advanced through a global Phase III clinical trial. In addition, Northwest Biotherapeutics is evaluating DCVax®-Direct, a novel formulation intended for direct injection into solid tumors, in Phase I/II studies. The company maintains an active pipeline exploring applications of its dendritic cell platform in other oncology indications.

Headquartered in Bethesda, Maryland, Northwest Biotherapeutics collaborates with research institutions and clinical centers across North America and Europe. These partnerships support ongoing trials, manufacturing scale-up, and regulatory interactions. The company’s leadership team comprises industry veterans with expertise in immunology, clinical development, and regulatory affairs, all working to advance personalized immunotherapy as a new standard of care in oncology.

View Northwest Biotherapeutics Profile
Earnings Tools